These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 30921804)

  • 1. Maintenance-Phase Subcutaneous Immunotherapy with House Dust Mites Induces Cyclic Immunologic Effects.
    Chaoul N; Albanesi M; Giliberti L; Rossi MP; Nettis E; Di Bona D; Caiaffa MF; Macchia L
    Int Arch Allergy Immunol; 2019; 179(1):37-42. PubMed ID: 30921804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy comparison and safety analysis of subcutaneous specific immunotherapy with standardized house dust mite allergen in patients with single and multiple allergic rhinitis].
    Huang HH; Xu C; Liu L; Chai RN
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun; 56(6):774-783. PubMed ID: 35785859
    [No Abstract]   [Full Text] [Related]  

  • 3. Different Responses in Induction of Allergen Specific Immunoglobulin G4 and IgE-Blocking Factors for Three Mite Subcutaneous Immunotherapy Products.
    Park KH; Lee SC; Son YW; Jeong KY; Shin YS; Shin JU; Sim da W; Park HJ; Lee JH; Lee KH; Park JW
    Yonsei Med J; 2016 Nov; 57(6):1427-34. PubMed ID: 27593871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmented type 2 inflammatory response in allergic rhinitis patients experiencing systemic reactions to house dust mite subcutaneous immunotherapy.
    Ji P; Yang L; Zhu L; Hu L; Wang Y; Shi C; Jiang Q; Huang N; Yang Y; Chen H; Zhu R
    Pediatr Allergy Immunol; 2024 Aug; 35(8):e14207. PubMed ID: 39092594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study.
    Bussmann C; Maintz L; Hart J; Allam JP; Vrtala S; Chen KW; Bieber T; Thomas WR; Valenta R; Zuberbier T; Sager A; Novak N
    Clin Exp Allergy; 2007 Sep; 37(9):1277-85. PubMed ID: 17845407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
    Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB
    J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dust mite component Analysis: Identifying key allergens components for effective immunotherapy in allergic rhinitis.
    Huang J; Xiang R; Tan L; Deng Y; Tao Z; Zhang W; Xu Y
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111111. PubMed ID: 37925948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune signatures predict response to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis.
    Wang N; Song J; Sun SR; Zhu KZ; Li JX; Wang ZC; Guo CL; Xiang WX; Tong YL; Zeng M; Wang H; Xu XY; Yao Y; Liu Z
    Allergy; 2024 May; 79(5):1230-1241. PubMed ID: 38403941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of rush-subcutaneous and sublingual immunotherapy with house dust mite extract for pediatric allergic rhinitis: A prospective cohort study.
    Hamada M; Saeki K; Tanaka I
    Allergol Int; 2023 Oct; 72(4):573-579. PubMed ID: 36918306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. House dust mite-specific immunotherapy alters the basal expression of T regulatory and FcεRI pathway genes.
    Pevec B; Radulovic Pevec M; Stipic Markovic A; Batista I; Rijavec M; Silar M; Kosnik M; Korosec P
    Int Arch Allergy Immunol; 2012; 159(3):287-96. PubMed ID: 22722803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma.
    Blumberga G; Groes L; Dahl R
    Allergy; 2011 Feb; 66(2):178-85. PubMed ID: 20883456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma.
    Hesse L; Petersen AH; Nawijn MC
    Methods Mol Biol; 2021; 2223():295-335. PubMed ID: 33226602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FcεRI expression and IgE binding by dendritic cells and basophils in allergic rhinitis and upon allergen immunotherapy.
    Berings M; Gevaert P; De Ruyck N; Derycke L; Holtappels G; Pilette C; Bachert C; Lambrecht BN; Dullaers M
    Clin Exp Allergy; 2018 Aug; 48(8):970-980. PubMed ID: 29682789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark.
    Rønborg S; Johnsen CR; Theilgaard S; Winther A; Hahn-Pedersen J; Andreasen JN; Olsen J
    J Med Econ; 2016 Aug; 19(8):735-41. PubMed ID: 26909663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of subcutaneous house dust mite immunotherapy in patients with moderate to severe allergic rhinitis.
    Valero A; Ibáñez-Echevarría E; Vidal C; Raducan I; Castelló Carrascosa JV; Sánchez-López J
    Immunotherapy; 2022 Jun; 14(9):683-694. PubMed ID: 35465692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration.
    Antúnez C; Mayorga C; Corzo JL; Jurado A; Torres MJ
    Pediatr Allergy Immunol; 2008 May; 19(3):210-8. PubMed ID: 18399897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases.
    Yang Y; Ma D; Huang N; Li W; Jiang Q; Wang Y; Wang X; Yang L; Zhu R
    Ital J Pediatr; 2021 Apr; 47(1):101. PubMed ID: 33892756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. House dust mite subcutaneous immunotherapy does not induce new sensitization to tropomyosin: does it do the opposite?
    Pevec B; Pevec MR; Markovic AS; Batista I
    J Investig Allergol Clin Immunol; 2014; 24(1):29-34. PubMed ID: 24765878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma.
    Richards JR; Stumpf JL
    Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.